Dexamethasone Acetate

• A Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffman… Not authorised
  2023-507633-21-00 Phase III 3 countries F. Hoffmann-La Roche AG
• A Clinical Trial of OM336 to Help Immunized Patients Become Eligible for Kidney Transplantation Not authorised
  2025-523222-40-00 Phase II 1 country Medical University Of Vienna
• TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: … Pending
  2024-511807-41-01 Phase III 1 country Assistance Publique Hopitaux De Paris
• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 Phase III 2 countries Intergroupe Francophone Du Myelome
• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Pending
  2025-522204-24-00 Phase II 4 countries Eli Lilly & Co.
• PAROCAINE : Evaluation of the Clinical Tolerance of an Intra-Parotid Injection of Bupivacaine Combined with Dexamethasone After Parotidectom… Pending
  2025-524358-32-00 Phase II 1 country Centre Hospitalier Universitaire De Nimes
• A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting
  2022-502910-10-00 Phase I (FiH) 4 countries Moderna Inc.
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting
  2023-504918-29-00 Phase III 16 countries Merck Sharp & Dohme LLC
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 Phase III 15 countries Merck Sharp & Dohme LLC
• Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting
  2023-506288-33-00 Phase I/II 8 countries Merck Sharp & Dohme LLC
• Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting
  2023-510128-66-00 Phase III 10 countries Merck Sharp & Dohme LLC
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 Phase III 15 countries Merck Sharp & Dohme LLC
• A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum… Recruiting
  2023-507751-30-00 Phase I/II 5 countries BeOne Medicines AG
• A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting
  2022-501725-21-00 Phase I 1 country Universitaet Muenster
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting
  2023-504899-25-00 Phase III 14 countries Merck Sharp & Dohme LLC
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 Phase III 14 countries Universitaetsklinikum Muenster AöR
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting
  2023-506987-15-00 Phase I/II 11 countries Merck Sharp & Dohme LLC
• A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended
  2023-506387-14-00 Phase I (FiH) 5 countries Merck Sharp & Dohme LLC
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended
  2023-508310-41-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended
  2023-504832-16-00 Phase II 8 countries Genmab A/S
• Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defec… Ended
  2024-511411-25-00 Phase III 6 countries Janssen Cilag International
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended
  2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
• Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extr… Ended
  2024-514963-24-00 Phase II 2 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended
  2023-506125-10-00 Phase III 11 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.

Showing 1–24 of 33 trials